metformin has been researched along with Fanconi Anemia in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Fanconi Anemia: Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voter, AF | 1 |
| Manthei, KA | 1 |
| Keck, JL | 1 |
| Pollard, JA | 1 |
| Furutani, E | 1 |
| Liu, S | 1 |
| Esrick, E | 1 |
| Cohen, LE | 1 |
| Bledsoe, J | 1 |
| Liu, CW | 1 |
| Lu, K | 1 |
| de Haro, MJR | 1 |
| Surrallés, J | 1 |
| Malsch, M | 1 |
| Kuniholm, A | 1 |
| Galvin, A | 1 |
| Armant, M | 1 |
| Kim, AS | 1 |
| Ballotti, K | 1 |
| Moreau, L | 1 |
| Zhou, Y | 1 |
| Babushok, D | 1 |
| Boulad, F | 1 |
| Carroll, C | 1 |
| Hartung, H | 1 |
| Hont, A | 1 |
| Nakano, T | 1 |
| Olson, T | 1 |
| Sze, SG | 1 |
| Thompson, AA | 1 |
| Wlodarski, MW | 1 |
| Gu, X | 1 |
| Libermann, TA | 1 |
| D'Andrea, A | 1 |
| Grompe, M | 2 |
| Weller, E | 1 |
| Shimamura, A | 1 |
| Ravera, S | 1 |
| Cossu, V | 1 |
| Tappino, B | 1 |
| Nicchia, E | 1 |
| Dufour, C | 1 |
| Cavani, S | 1 |
| Sciutto, A | 1 |
| Bolognesi, C | 1 |
| Columbaro, M | 1 |
| Degan, P | 1 |
| Cappelli, E | 1 |
| Zhang, QS | 1 |
| Tang, W | 1 |
| Deater, M | 1 |
| Phan, N | 1 |
| Marcogliese, AN | 1 |
| Li, H | 1 |
| Al-Dhalimy, M | 1 |
| Major, A | 1 |
| Olson, S | 1 |
| Monnat, RJ | 1 |
| Crossan, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Metformin for Patients With Fanconi Anemia[NCT03398824] | Phase 2 | 15 participants (Actual) | Interventional | 2018-03-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Hematologic response is defined by specific increases in erythroid, platelet, and neutrophil counts.~Erythroid response: Hemoglobin (Hgb) increase by >1.5g/dL for non-transfusion dependent patients and for patients who are transfusion dependent: Transfusion independence Only transfusions given for Hgb ≤8g/dL or for symptoms will be counted in the response evaluation~Platelet response: If initially <20k/uL to start, then must increase to >20k/UL with an absolute increase of 100%. If initially ≥20k/uL to start, then must have an absolute increase of >30k/UL~Neutrophil response: If initially <500/uL to start, then must increase to >500/uL with an absolute increase of > 250/uL. If initially ≥500/uL to start, then must have an absolute increase of >500/uL" (NCT03398824)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 4 |
1 trial available for metformin and Fanconi Anemia
| Article | Year |
|---|---|
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia.
Topics: Child; Fanconi Anemia; Humans; Metformin; Young Adult | 2022 |
4 other studies available for metformin and Fanconi Anemia
| Article | Year |
|---|---|
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Topics: Antineoplastic Agents; DNA Damage; DNA Helicases; DNA Repair; Drug Screening Assays, Antitumor; Fanc | 2016 |
Concentration-dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells.
Topics: AMP-Activated Protein Kinases; Case-Control Studies; Cell Survival; DNA Damage; Dose-Response Relati | 2018 |
Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice.
Topics: Aldehydes; Animals; Blood Cell Count; Bone Marrow Cells; Carcinogenesis; Cell Cycle; Chromosome Brea | 2016 |
Metformin: treating the cause of Fanconi anemia?
Topics: Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Grou | 2016 |